How common is chemotherapy-induced nausea and vomiting in breast cancer patients?
Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of breast cancer treatment. A meta-analysis of 12 studies found that about 48% of breast cancer patients experience CINV 1. This means nearly half of patients are affected. Certain factors, such as being younger than 45 or having a history of motion sickness, can increase the risk 1. Effective antiemetic medications are available to help prevent and control these symptoms 345.
What the research says
A 2025 meta-analysis of 12 studies reported that the overall prevalence of CINV in breast cancer patients is 48% 1. The same analysis identified key risk factors: being age 45 or younger (about 3 times higher odds), having a history of motion sickness (about 5 times higher odds), and receiving 3 or more chemotherapy cycles (about 2 times higher odds) 1. Anxiety and other health conditions were not found to significantly increase risk 1.
Standard antiemetic treatments include 5-HT3 receptor antagonists like ondansetron, which is FDA-approved to prevent nausea and vomiting from cancer chemotherapy 3. A network meta-analysis of 36 trials found that palonosetron (a newer 5-HT3 antagonist) is generally more effective than older ones, especially for delayed vomiting 4. Adding dexamethasone to these drugs further improves control 4. For highly emetogenic chemotherapy, NK1 receptor antagonists like fosaprepitant are also approved for use in combination with other antiemetics 5.
Complementary approaches may help. A 2022 randomized trial in 114 breast cancer patients found that auricular acupressure (ear acupressure) plus standard care improved CINV outcomes compared to standard care alone, with true acupressure showing larger effects 6. A 2024 meta-analysis of acupressure studies concluded that acupressure combined with antiemetics significantly reduces the severity of acute nausea, delayed nausea, and delayed vomiting in breast cancer patients 7.
For patients with solid tumors receiving highly emetogenic chemotherapy, a 2024 phase 3 trial found that low-dose olanzapine (2.5 mg) was non-inferior to standard-dose (10 mg) when added to triple antiemetic therapy, with less daytime sleepiness 8. This suggests that lower doses may be an option for some patients.
What to ask your doctor
- What is my personal risk for chemotherapy-induced nausea and vomiting based on my age, treatment plan, and medical history?
- Which antiemetic medications (such as ondansetron, palonosetron, or fosaprepitant) are recommended for my chemotherapy regimen?
- Could a lower dose of olanzapine be an option to reduce side effects like sleepiness?
- Are there complementary therapies like acupressure that might help manage my nausea and vomiting?
- How should I monitor and report my symptoms so we can adjust my treatment if needed?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.